128 related articles for article (PubMed ID: 38240035)
1. Chimeric antigen receptor T-cells might unmask transdifferentiated histiocytic sarcoma during diffuse large B-cell lymphoma treatment.
Gravenmier C; Shah B; Hussaini M; Zhang L
Leuk Lymphoma; 2024 May; 65(5):674-678. PubMed ID: 38240035
[No Abstract] [Full Text] [Related]
2. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
[TBL] [Abstract][Full Text] [Related]
3. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with cells.
Chong EA; Porter DL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):590-597. PubMed ID: 33275723
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Yu M; Zhang Q; Xu S; Yin T; Li F
Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
[TBL] [Abstract][Full Text] [Related]
6. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Kersten MJ; van Ettekoven CN; Heijink DM
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31722870
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma.
Deol A; Uberti J
Am J Hematol; 2020 Mar; 95(3):333-334. PubMed ID: 31429117
[No Abstract] [Full Text] [Related]
8. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
9. Tiny transformed diffuse large B cell lymphoma localized to the left conjunctiva.
Harada N; Tagami M; Koh H; Ohsawa M; Hino M; Nakamae H
Int J Hematol; 2021 Oct; 114(4):413-414. PubMed ID: 34424492
[No Abstract] [Full Text] [Related]
10. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
11. Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
Lunning MA; Armitage JO
Haematologica; 2015 Jul; 100(7):853-5. PubMed ID: 26130511
[No Abstract] [Full Text] [Related]
12. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
14. Successful Continuation of Clozapine in Conjunction With Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy: Case Report.
Kutzke JL; Leung JG; May HP; Nedved AN; DeFino CE; Bennani NN
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e194-e197. PubMed ID: 33272906
[No Abstract] [Full Text] [Related]
15. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
17. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
18. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
Spinner MA; Advani RH
Oncology (Williston Park); 2022 Jan; 36(1):51-58. PubMed ID: 35089671
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
20. Double-hit lymphoma: optimizing therapy.
Dunleavy K
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):157-163. PubMed ID: 34889402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
